School of Medicine
Showing 1-50 of 81 Results
-
Steven Artandi, MD, PhD
Laurie Kraus Lacob Director of the Stanford Cancer Institute (SCI), Jerome and Daisy Low Gilbert Professor and Professor of Biochemistry
Current Research and Scholarly InterestsTelomeres are nucleoprotein complexes that protect chromosome ends and shorten with cell division and aging. We are interested in how telomere shortening influences cancer, stem cell function, aging and human disease. Telomerase is a reverse transcriptase that synthesizes telomere repeats and is expressed in stem cells and in cancer. We have found that telomerase also regulates stem cells and we are pursuing the function of telomerase through diverse genetic and biochemical approaches.
-
Ami Bhatt
Professor of Medicine (Hematology) and of Genetics
Current Research and Scholarly InterestsThe Bhatt lab is exploring how the microbiota is intertwined with states of health and disease. We apply the most modern genetic tools in an effort to deconvolute the mechanism of human diseases.
-
Linda Boxer, MD, PhD
Vice Dean of the School of Medicine and Stanley McCormick Memorial Professor
Current Research and Scholarly InterestsRegulation of expression of oncogenes in normal and malignant hematologic cells.
-
Rondeep Brar
Clinical Professor, Medicine - Hematology
BioAs the Medical Director of the Stanford Cancer Center and Associate Director for Clinical Care at the Stanford Cancer Institute, it is my privilege to partner with my colleagues in advancing innovative research alongside high quality, coordinated, and compassionate care.
I aim to provide high quality care in a diverse patient practice. My clinic includes all types of hematologic disorders, ranging from anemia, clotting/bleeding disorders, and low blood counts to complex malignancies such as leukemia, myelodysplastic syndrome, myeloma, and lymphoma. I aim to combine the efficiency of a private office with the complex care expected of a tertiary institution like Stanford. I value your time and strive to maintain an on-schedule clinic. -
Robert Diep, MD
Clinical Assistant Professor, Medicine - Hematology
BioDr. Diep is a board-certified, fellowship-trained hematologist with Stanford’s Hematology Program and Hematologic Cancer Program. He is also a clinical assistant professor with the Department of Medicine, Division of Hematology.
He diagnoses and treats patients with a wide range of nonmalignant hematology conditions. His special interests include clotting disorders, bleeding disorders, hemoglobinopathies, and disorders affecting blood count. Subspecialty interests include anticoagulation and thrombosis.
Dr. Diep’s practice style emphasizes shared decision-making by building patient-physician relationships and using the best available evidence to create treatment plans. He is passionate about improving care for patients with blood disorders and has helped expand access to hematology care by launching an electronic consult service for primary care providers.
Dr. Diep’s research interests include anticoagulation, thrombosis, and bleeding disorders. He has participated in research projects that have received funding from the National Heart, Lung, and Blood Institute.
Dr. Diep has published in multiple peer-reviewed journals, and has presented to his peers at national and regional meetings.
He is a member of the American Society of Hematology, American Society of Clinical Oncology, Hemostasis and Thrombosis Research Society, International Society of Hemostasis and Thrombosis, and Anticoagulation Forum. Dr. Diep serves as quality director for the Division of Hematology. -
Tamara Dunn
Clinical Associate Professor, Medicine - Hematology
BioDr. Tamara Dunn is a clinical associate professor in the Division of Hematology at the Stanford University School of Medicine. She is a clinician with a special interest in medical education, diversity, equity, and inclusion. Specifically, she is committed to improving workforce diversity and creating inclusive workplaces. She is currently the Program Director for the Stanford Hematology/Oncology Fellowship and one of the Associate Chairs of Diversity and Inclusion for the Department of Medicine at Stanford. She is a member of the inaugural American Society of Hematology (ASH) Ambassador Cohort and serves on the ASH Women in Hematology committee, which she co-chairs. She is on the steering committee and is a mentor for Stanford’s Leadership Education in Advancing Diversity (LEAD) program. She takes pride in treating underserved veterans at the Palo Alto Veterans Hospital, where she sees both classical and malignant hematology. Outside of medicine she enjoys singing, dancing, sports (Go Chiefs! Go Warriors!), board games, movies, and spending time with friends and family including her 3 young children, spouse, and energetic vizsla Casey.
-
Asiri Ediriwickrema MD, PhD
Instructor, Medicine - Hematology
BioInstructor in Hematology
-
Bita Fakhri, MD, MPH
Assistant Professor of Medicine (Hematology)
BioDr. Bita Fakhri is Assistant Professor of Medicine in the Division of Hematology at Stanford University School of Medicine. She specializes in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), hairy cell leukemia, and other hematologic malignancies. As a clinical scientist, Dr. Fakhri is dedicated to caring for patients, teaching trainees, and researching novel therapies for patients with CLL/SLL. Dr. Fakhri has co-authored numerous publications on topics including CLL, novel targeted agents, and cellular therapies for patients with hematologic malignancies. Currently, Dr. Fakhri is the director of the CLL clinical trial portfolio at Stanford. Additionally, in her role as the DEI ambassador of the Division of Hematology, her main focus is to enhance trial equity among underserved and marginalized populations in the Stanford catchment area.
-
Jason Gotlib
Professor of Medicine (Hematology)
Current Research and Scholarly InterestsMy research interests include phase I/II clinical trial evaluation of novel therapies for the following diseases:
--Myelodysplastic syndromes (MDS)
--Chronic myelogenous leukemia (CML)
--Acute myelogenous leukemia (AML)
--Myeloproliferative disorders (MPDs) including:
Hypereosinophilic syndrome
Systemic mastocytosis
BCR-ABL-negative MPDs -
Peter Greenberg
Professor of Medicine (Hematology), Emeritus
Current Research and Scholarly InterestsDr Greenberg's clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. These studies are particularly based on his prior laboratory investigations of gene expression and hematopoietic regulation in MDS patients. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and the mutation-based prognostic risk system, the IPSS-Molecular (IPSS-M). This project uses such findings to more specifically characterize and treat MDS patients. He is Chair of the NCCN Practice Guidelines Panel for MDS.
-
David Iberri
Clinical Associate Professor, Medicine - Hematology
BioDr. Iberri is a hematologist who specializes in the treatment of multiple myeloma, Waldenström macroglobulinemia, and other blood and bone marrow disorders. He is actively involved in clinical research evaluating novel agents in hematologic malignancies. His research interests include the development and application of biomarkers to select patients most likely to benefit from therapy, and in the development of blood tests to reduce the need for bone marrow biopsies in myeloma disease monitoring.
-
Thulasee Jose
Affiliate, Department Funds
Fellow in Medicine - Med/HematologyBioFellow - Hematology & Medical Oncology ( Pathway Research Track)
-
Calvin Kuo
Maureen Lyles D'Ambrogio Professor
Current Research and Scholarly InterestsWe study cancer biology, intestinal stem cells (ISC), and angiogenesis. We use primary organoid cultures of diverse tissues and tumor biopsies for immunotherapy modeling, oncogene functional screening and stem cell biology. Angiogenesis projects include blood-brain barrier regulation, stroke therapeutics and anti-angiogenic cancer therapy. ISC projects apply organoid culture and ko mice to injury-inducible vs homeostatic stem cells and symmetric division mechanisms.
-
Lawrence Leung
Maureen Lyles D'Ambrogio Professor in the School of Medicine
Current Research and Scholarly InterestsOur long term interest is to have a better understanding of the natural antithrombotic pathways and the pathophysiology of vascular thrombosis. We have focused on thrombin, the key enzyme in the blood clotting cascade.Our goal is to develop new antithrombotic agents and devise new diagnostic tests for vascular thrombotic disorders.
-
Lee Levitt
Professor of Medicine (Hematology) at the Santa Clara Valley Medical Center, Emeritus
Current Research and Scholarly InterestsLow molecular-weight heparins Clinical trials with anti-thrombotics Clinical trials in patients with leukemia, breast cancer and myeloma Medical education.
-
Michaela Liedtke
CKD Family Professor
Current Research and Scholarly Interests1) Design of phase I/II trials for the treatment of Multiple Myeloma and Amyloidosis
2) Conduct of clinical trials to improve the treatment of patients with acute lymphoblastic leukemia (ALL)
3) Outcomes research using clinical databases for patients with Multiple Myeloma and Amyloidosis -
Sydney X. Lu
Assistant Professor of Medicine (Hematology)
BioSydney Lu is an assistant professor and physician-scientist in the Division of Hematology, Department of Medicine with a broad interest in both normal and abnormal RNA processing in the context of normal physiology and disease states. The laboratory studies translational questions regarding the mechanistic basis of RNA processing abnormalities in malignant blood disorders, their implications for leukemogenesis and cancer biology, as well as resultant therapeutic opportunities.
As a physician, Sydney’s group is particularly focused on dissecting RNA processing abnormalities in primary patient samples and disease-relevant preclinical model systems. Lab members employ a variety of ‘wet-lab’ and computational approaches to study transcriptome abnormalities in (1) states of immune dysfunction, (2) myeloid blood cancers such as myelodysplastic syndromes and acute myeloid leukemia, and (3) lymphoid blood cancers such as chronic lymphocytic leukemia. Additional projects are focused on novel therapeutics, including multiple targeted agents which modulate RNA processing, for the selective treatment of these diseases.
Sydney’s research is/has been supposed by grant funding from the National Cancer Institute, Parker Institute for Cancer Immunotherapy, Leukemia & Lymphoma Society, Aplastic Anemia & Myelodysplastic Syndromes International Foundation, the American Society for Clinical Oncology, the American Society of Hematology, the American Association for Cancer Research, the Paula and Rodger Riney Foundation, the Doris Duke Charitable Foundation, The Gabrielles Angel Foundation for Cancer Research, and the Stanford Cancer Institute. -
Gabriel Mannis
Associate Professor of Medicine (Hematology)
Current Research and Scholarly InterestsMy research focuses on the development of more effective, less toxic therapies for patients with AML and other high-risk hematologic malignancies. We study biologic correlates that predict response to therapy as well as factors/interventions that improve quality-of-life for patients struggling with blood-borne cancers.
-
Bruno Medeiros
Adjunct Clinical Associate Professor, Medicine - Hematology
Current Research and Scholarly InterestsMy clinical activities combine the development of novel therapeutic modalities, translational research activities and epidemiological study of acute leukemia. My special focus is on the development of better, patient tailored therapies for young and elderly patients with acute leukemia.
-
Masashi Miyauchi
Basic Life Research Scientist, Medicine - Med/Hematology
BioMasashi Miyauchi, MD, PhD, is a physician-scientist specializing in hematology, oncology, immunology, and stem cell biology, with over a decade of experience in clinical hematology and oncology. Dr. Miyauchi's academic career commenced at Kyoto University, where he obtained his MD in Medicine. He furthered his expertise with a PhD in Internal Medicine from The University of Tokyo, Graduate School of Medicine. Following his comprehensive clinical training and professional appointments at The University of Tokyo Hospital, Dr. Miyauchi embarked on a postdoctoral journey at Stanford University in the Nakauchi lab, starting in July 2019.
Dr. Miyauchi's clinical training is extensive, including a Senior Residency in Internal Medicine and a Clinical Fellowship in Hematology and Oncology at The University of Tokyo Hospital. This period was complemented by his participation in a Cancer Professional Training Plan. After completing his clinical fellowship, Dr. Miyauchi has served in various pivotal roles at The University of Tokyo Hospital and The University of Tokyo. His positions as a clinically-focused Project Assistant Professor and Assistant Professor in the Department of Hematology and Oncology have enabled him to contribute significantly to pioneering research and education for the next wave of medical professionals.
In his PhD research, Dr. Miyauchi specialized in the disease modeling of cancers and cancer stem cells, employing cancer patient-specific induced pluripotent stem cells (iPSCs). His work with iPSCs notably includes scalable ex vivo manufacturing of human neutrophils. In his postdoctoral research under the guidance of Dr. Hiromitsu Nakauchi in Genetics at Stanford, Dr. Miyauchi has been concentrating on developing a stable hematopoietic stem cell (HSC) expansion system in both mouse and human models. His research is focused on exploring the potential applications of this expansion system, underlining his commitment to advancing the fields of stem cell biology, regenerative medicine and oncology. -
Ann Mullally
Professor of Medicine (Hematology)
Current Research and Scholarly InterestsDr. Ann Mullally's aboratory studies the genetics, biology and therapy of myeloid blood cancers, with a focus on myeloproliferative neoplasms (MPN). Using primary human samples, mouse models, genomics, single-cell sequencing and CRISPR, as well as cellular and molecular biology, the lab has investigated the key genetic events underlying MPN pathogenesis. Dr. Mullally’s lab elucidated the mechanism by which mutant calreticulin (CALR) is oncogenic and causes MPN.
-
Michitaka Nakano
Basic Life Research Scientist, Medicine - Med/Hematology
BioI am a MD/PhD postdoctoral fellow and medical oncologist with a long-standing interest in translational cancer research. My long-term goal is to be a lab-based physician-scientist and independent academic researcher, translating basic cancer research, and mentoring next-generation scientists. My thesis work in Japan focused on cancer stem cell equilibrium by uniquely applying organoid culture as a method to elucidate cancer stem cell dynamics, which was awarded in Japanese Cancer Association. Along with the development of the field represented by success in T cell checkpoint, my interest gradually shifted to immune oncology while I examined numerous numbers of cancer patients as a medical oncology fellow. My postdoctoral fellowship at Calvin Kuo Lab in Stanford (2019-present) focuses on tumor immune microenvironment. Kuo lab developed a unique 3D air-liquid interface (ALI) organoid system that cultures tumors while preserving their endogenous infiltrating immune cells (T,B ,NK, Myeloid cells). My postdoctoral work will prove the significance of organoids as a translational tool to discover tumor-immune interaction by novel checkpoint inhibitors for immune cells, which can be broadly applicable to basic cancer biology, precision medicine, therapeutics validation and biomarker discovery.
